SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--True North Therapeutics, a clinical stage biotechnology company developing novel therapies that selectively inhibit the Complement system to treat rare diseases, today announced that a late-breaking abstract describing clinical data from its ongoing Phase 1b clinical study of TNT009 in patients with Cold Agglutinin Disease (CAD) has been selected for presentation at the 21st Congress of the European Hematology Association (EHA) held June 9-12, 2016 in Copenhagen.
